Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Androgens and COVID-19
May 2020
SHARING OPTIONS:

IRVINE, Calif.—Applied Biology and Brown University researchers have highlighted a potential new indicator of COVID-19 mortality risk: the androgen receptor. Their joint research effort has suggested that human type II pneumocytes androgen sensitivity could serve as a treatment marker, and Applied Biology intends to launch a drug discovery platform based on this discovery.
 
Dr. Carlos G. Wambier, director of Cosmetic Research at the Department of Dermatology of the Alpert Medical School of Brown University, explained, “We believe that androgens are required for the expression of the serine protease TMPRSS2. This proteolytic priming of the spikes of the coronavirus is the first step required for binding to the ACE2 receptor in cells. Male hormones might also affect ACE2 receptor expression in lung cells. To the best of our knowledge, these are required for the novel coronavirus to infect humans.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.